Oncology · Small Cell Lung CancerTrial Updateclinicalmid-term

Phase 2 Study of Ivonescimab and Irinotecan Liposome in Relapsed SCLC

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/28/2026, 12:31:12 PM

Assessment confidence: 73% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing phase 2 study of ivonescimab combined with irinotecan liposome could establish a new second-line treatment for relapsed small cell lung cancer, potentially reshaping the competitive landscape in oncology. Pharma strategy teams should closely monitor the trial's outcomes to evaluate implications for their portfolios and competitive positioning. Regulatory context from FDA (Sunscreen: How to Help Protect Your Skin from the Sun) supports the near-term read. Assessment grounded in 13 ranked evidence items (8 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential of ivonescimab in the context of existing SCLC treatments and consider strategic partnerships or investments. The strongest clinical anchor is A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for SCLC (ClinicalTrials.gov), sub-indication match (lung cancer); entity match (ivonescimab). In lung cancer, 0 regulatory and 2 competitive items passed relevance filtering for Ivonescimab.

Competitive Pressure

The most relevant competitive pressure comes from Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC (Humanexa Signals) — sub-indication match (lung cancer); sponsor/company relevance (pfizer). Secondary pressure from Merck's KEYMAKER-U01 Study Explores Pembrolizumab in NSCLC with Chemotherapy. This trial could position ivonescimab as a viable second-line treatment option, impacting competitive dynamics in SCLC therapies.

Regulatory Outlook

Regulatory risk is concentrated around The trial results will inform potential regulatory submissions and label expansions, impacting compliance and approval timelines for new treatment options..

Key Risks

Elevated medium regulatory exposure for Ivonescimab could delay market entry or constrain labeling if agency review intensifies.
Evidence gap: no medium- or high-relevance regulatory precedents in ingested corpus.

Key Opportunities

If successful, ivonescimab could capture market share from existing therapies, influencing revenue streams and competitive dynamics in the SCLC treatment market.
Lead sponsor: Zhejiang Cancer Hospital. This is an open-label, single-arm, prospective phase 2 study, evaluating the efficacy and safety of ivonescimab combined with irinotecan liposome for relapsed small cell lung cancer, who progressed on PD-(L)1 -based first-line therapy.
Oncology · NSCLC · Trial Update · These results position LORBRENA as a preferred standard of care over XALKORI in ALK-positive advanced NSCLC, potentially shifting treatment paradigms.
Upside for Ivonescimab may improve if A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC) (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Ivonescimab may improve if A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) (ClinicalTrials.gov) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and any announcements regarding efficacy and safety outcomes.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Sunscreen: How to Help Protect Your Skin from the Sun
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View source

A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for SCLC
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Entity match (ivonescimab)
FDA document
View source
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Merck)
FDA document
View source
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Merck)
FDA document
View source
A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer)
FDA document
View source
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer)
FDA document
View source
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
ClinicalTrials.govmedium relevance
Sub-indication match (lung cancer)
FDA document
View source
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
ClinicalTrials.govmedium relevance
Sub-indication match (lung cancer)
FDA document
View source

Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Pfizer)
Merck's KEYMAKER-U01 Study Explores Pembrolizumab in NSCLC with Chemotherapy
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Merck)
SEC61G identified as a pan-cancer biomarker and potential therapeutic target
Humanexa Signalslow relevance
Broad oncology match without sub-indication specificity
Epcoritamab Shows Promise in High-risk Burkitt Lymphoma with DA-EPOCH-R in Phase II Trial
Humanexa Signalslow relevance
Broad oncology match without sub-indication specificity

Inhibition of STAT3-mediated glycolysis by bruceine D suppresses non-small-cell lung cancer progression in vitro and in vivo.
PubMedhigh relevance
Sub-indication match (lung cancer)
FDA document
View source
Microwave hyperthermia enhances radiosensitivity of highly invasive non-small cell lung cancer cells via inhibiting Sonic Hedgehog signaling pathway.
PubMedmedium relevance
Sub-indication match (lung cancer)
FDA document
View source
CXCL13-expressing CD4(+) T cells coordinate the lymphocytes triad to promote the anti-tumor immunity in NSCLC.
PubMedmedium relevance
Sub-indication match (lung cancer)
FDA document
View source
Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated adv
PubMedmedium relevance
Sub-indication match (lung cancer)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Ivonescimab
Small Cell Lung Cancer therapies

Commercial impact

medium

If successful, ivonescimab could capture market share from existing therapies, influencing revenue streams and competitive dynamics in the SCLC treatment market.

Regulatory impact

medium

The trial results will inform potential regulatory submissions and label expansions, impacting compliance and approval timelines for new treatment options.

What to watch

Monitor trial results and any announcements regarding efficacy and safety outcomes.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.